GlassScriptPhysician profile
Mark R Wilson
NPI 1831455450
$5,549.03
in general payments reported to CMS, 2019-2025
24 companies · $508 in 2025
The $508 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $198 · 2021: $54.24 · 2022: $544 · 2023: $2,546 · 2024: $1,049 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355 · Travel and Lodging: $1,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.37 |
| Travel and Lodging | $1,748.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $4,199.57 | 2019-2025 | Novostitch, Ultrabutton, Healicoil |
| Peerless Surgical INC. | $499.46 | 2023-2025 | |
| Anika Therapeutics, INC. | $288.27 | 2023 | Ovomotion, X-Twist, Tactoset |
| Zimmer Biomet Holdings, INC. | $73.39 | 2020-2022 | |
| Ermi LLC | $48.03 | 2019-2020 | |
| Forte Bio-Pharma LLC | $43.53 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.20 | 2020 | |
| Orthogenrx INC. | $38.34 | 2021 | |
| Pacira Therapeutics, INC. | $37.24 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $28.45 | 2022-2023 | Eliquis |
| Surgalign Spine Technologies, INC. | $28.33 | 2019 | |
| Dynasplint Systems INC. | $28.28 | 2019 | |
| Vericel Corporation | $24.90 | 2019 | |
| Innocoll Pharmaceuticals Limited | $24.59 | 2023 | Posimir |
| Innovation Technologies INC | $18.88 | 2025 | Irrisept |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $17.43 | 2022 | |
| Avanos Medical | $17.42 | 2022 | |
| Stryker Corporation | $16.57 | 2019 | |
| Medline Industries LP | $14.61 | 2024 | |
| Acelrx Pharmaceuticals, INC. | $12.37 | 2019 | |
| Baudax Bio INC. | $11.99 | 2020 | |
| Medtronic USA, INC. | $11.92 | 2019 | |
| Kerecis Limited | $11.73 | 2020 | |
| Linvatec Corporation | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.